Hatice Bölek

Our review on DDIs in prostate Ca is now published @ESMO_Open! @coskunyazgann Thanks to @DrYukselUrun @Silke_Gillessen @DrRanaMcKay @yekeduz_emre and Marina Kaymakcalan for their support. authors.elsevier.com/sd/article/S20…

Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer @ASCO ascopubs.org/doi/10.1200/ED…

The authors’ response: ascopubs.org/doi/10.1200/JC…

Our correspondence on the LUNAR trial is now published in JCO. @DrYukselUrun @JCO_ASCO ascopubs.org/doi/10.1200/JC…

Phase 3 LITESPARK-011: Belzutifan + Lenvatinib vs Cabozantinib in pretreated metastatic clear cell renal cancer #GU25 shows +ve PFS HR 0.75 , OS HR 0.85 (non-significant), ⬆️ RR 53% vs 40%, G3+ TRAEs 72% vs 66%. Cabozantinib is hard to beat making this a standard of care. Using the most active drugs first rather than sequencing is debatable, but not all patients can sequence. We still don’t have significant OS post in IO refractory RCC @OncoAlert

An Editorial on a Clinical Grey Zone: cN+ M0 Bladder Cancer Regional Node–positive Bladder Cancer: Therapeutic Decisions Based on Trial Results in Perioperative and Advanced Disease Settings europeanurology.com/article/S0302-… @EUplatinum @PGrivasMDPhD

Huge congrats to brilliant mentees @hatice_bolek @coskunyazgann and mente/mentor @yekeduz_emre Big thanks to @DrChoueiri @montypal @BradMcG04 and @DrRanaMcKay for their outstanding contributions, guidance, and support! 🔑IO rechallenge + VEGF TKI no survival gain in mRCC. @OncJournal @OncoAlert @Ankaratip1945 @AnkaraUni @IKCCorg @kidneycan @KidneyCancer @Uromigos doi.org/10.1093/oncolo…

@MuslihUrun Teşekkür ederim abi ☺️

@hatice_bolek Tebrikler 👏👏👏

Happy to share that I passed the @myESMO Examination 2025 among the Top 5 performers and was included in the ESMO Exam Talent Pool 🎉 I would like to sincerely thank my mentors at @AUTF_DEKANLIK for their invaluable support throughout my education. @DrYukselUrun @yekeduz_emre

@hatice_bolek @myESMO @AUTF_DEKANLIK @yekeduz_emre Proud mentor moment. Heartfelt congrats, Hatice! This success is not luck. The future is bright! @myESMO @hatice_bolek @onkolojidernegi

@DenizCanGuven1 @DrYukselUrun @yekeduz_emre Thank you for your kind words and for always supporting your juniors.

Exciting and proud news for Turkish Oncology Community 🇹🇷🇹🇷 Great to see the academic journey of our fantastic young collague @hatice_bolek with the guidance of @DrYukselUrun and @yekeduz_emre 👏👏 Sky is the limit 💯💯

It was a great experience to participate in the @myESMO Preceptorship on Prostate Cancer and to present a case in the session chaired by my mentor, @DrYukselUrun If you haven’t attended before, you should definitely consider joining next year.

📢 Out now one of the largest real-world cohorts on adjuvant pembrolizumab for RCC by @aron_project 🔬 An important step forward in understanding how to optimize the management of renal cell carcinoma in real-life settings. @IntKidneyCancer @OncoAlert @Uroweb

@DrYukselUrun Thank you for making this journey even more meaningful and for guiding me along the way. Couldn’t have asked for a better mentor. 🙏🏻

Congrats on finishing this chapter. May the next one be just as meaningful. Wishing you the best for what comes next. Keep shining. 👏👏👏🍀

@Onco_Cifu88 Thank you Sergio!

@hatice_bolek Congrats @hatice_bolek !!!

End of the medical oncology residency 🎉 This has been a great and inspiring journey. I am deeply grateful to my mentors and professors who lit my way, and to my colleagues, friends, and family for accompanying me throughout this journey. What’s next 🤔

@dr_yakupergun Çok teşekkür ederim ☺️

@hatice_bolek Tebrik ederim Hatice👏 Yolun açık olsun💫

🔬 We're back with our new study: Bellmunt Risk Score in Prostate Cancer Significant survival difference in mCSPC: • Low-risk: 44.4 months OS • High-risk: 14.1 months OS • p<0.001 📈 ✅ Simple: ECOG + hemoglobin + liver metastases ✅ Works with docetaxel & ARPi ✅ Better than CHAARTED/LATITUDE (C-index: 0.67) A promising tool for risk stratification, although the incremental benefit is modest. @hatice_bolek @mcpinar @yekeduz_emre @DrYukselUrun #JoaquimBellmunt #ProstateCancer #Oncology #mCSPC 📖 Full article: doi.org/10.1002/pros.7…

In 6 🇹🇷 centers, #mCRPC pts treated with 177Lu-PSMA-617, prior #enzalutamide (vs #abiraterone) linked to ⬆️ PFS (7.6 vs 5.3 mo, P=0.068), ⬆️ OS (12.8 vs 6.9 mo, P=0.021) Sequencing is 🔑 #GUonc @susanebates @gbanna74 @PasRescigno doi.org/10.1093/oncolo…

A review of the #TKCC database shows in metastatic #kcsm that smoking 🚬is 🔗 to worse outcomes w/ #nivolumab in 2nd line. ⬇️ #OS (16.8 vs 32.3 mo) & ⬆️ time to failure. This may motivate patients or #policymakers on smoking cessation 🚭 #prevention doi.org/10.1093/oncolo…

Congrats to all who made this possible. This trial showed 53% pCR and 64% 2‑yr EFS with neoadjuvant chemo‑immunotherapy in non-urothelial MIBC subtypes. Time for collaboration and more studies in this neglected population. @RubenRaychaud @arkhaki @spsutkaMD @PGrivasMDPhD @EUplatinum @WorldBladderCan doi.org/10.1016/j.euru…